Cost-effectiveness of broadly neutralizing antibodies for HIV prophylaxis for infants born in settings with high HIV burdens

PLoS ONE, Journal Year: 2025, Volume and Issue: 20(3), P. e0318940 - e0318940

Published: March 19, 2025

Background Approximately 130 000 infants acquire HIV annually despite global maternal antiretroviral therapy scale-up. We evaluated the potential clinical impact and cost-effectiveness of offering long-acting, anti-HIV broadly neutralizing antibody (bNAb) prophylaxis to in three distinct settings. Methods simulated Côte d’Ivoire, South Africa, Zimbabwe using Cost-Effectiveness Preventing AIDS Complications-Pediatric (CEPAC-P) model. modeled strategies a three-bNAb combination addition WHO-recommended standard-of-care oral infants: a) with known, WHO-defined high-risk exposure at birth ( HR-HIVE ); b) known HIVE or c) without ALL ). Modeled received 1-dose , 2-doses Extended (every 3 months through 18 months) bNAb dosing. Base case model inputs included 70% efficacy (sensitivity analysis range: 10–100%), 3-month duration/dosing interval (1–6 months), $20/dose cost ($5–$100/dose). Outcomes pediatric infections, life expectancy, lifetime HIV-related costs, incremental ratios (ICERs, US$/year-of-life-saved [YLS], assuming ≤ 50% GDP per capita threshold). Findings The base projects that targeting would prevent 7–26% 10–42% additional respectively, compared alone, ranging by dosing approach. HIVE-Extended be cost-effective (cost-saving standard-of-care) d’Ivoire Zimbabwe; ALL-Extended Africa (ICER: $882/YLS). BNAb result greater costs smaller expectancy gains than . Throughout most efficacies sensitivity analyses, Zimbabwe, Africa. Interpretation Adding long-acting bNAbs current cost-effective, plausible costs. target population vary setting, largely driven antenatal prevalence postpartum incidence.

Language: Английский

---

Manufacturing innovation is essential for monoclonal antibody affordability and access

Nature Reviews Bioengineering, Journal Year: 2025, Volume and Issue: unknown

Published: April 17, 2025

Language: Английский

---

Modeling and Optimization of Recombinant Tocilizumab Production From Pichia pastoris Using Response Surface Methodology and Artificial Neural Network

Biotechnology and Bioengineering, Journal Year: 2025, Volume and Issue: unknown

Published: May 15, 2025

ABSTRACT This study has demonstrated the optimization of defined medium that significantly enhanced production recombinant monoclonal antibody (mAb) Tocilizumab (TCZ) as full‐length and Fab fragment from Pichia pastoris . Out four tested media, FM22 was found to be suitable for growth strains yield. Among various carbon nitrogen sources tested, mannitol glycine, respectively, were TCZ. Similarly, sorbitol ammonium sulfate sources, Fab. The components influenced TCZ mannitol, histidine, K 2 SO 4 sorbitol, sulfate, KH PO , CaSO .2H O Fab, using a two‐level factorial Plackett‐Burman design. screened optimized response surface methodology (Box‐Behnken Design). Artificial neural network (ANN) models combined with genetic algorithms (GA) further improved predictions showed remarkable impact on mAb in P. Under optimal levels components, determined 0.35 mg/L 0.42 g/L, shake‐flask culture. yield batch reactor (2‐L culture) 0.44 0.45 at components. overall increased yields observed 3.8 2.9‐folds respectively.

Language: Английский

---

Peptide-Based Regulation of TNF-α-Mediated Cytotoxicity

Biomolecules, Journal Year: 2025, Volume and Issue: 15(4), P. 559 - 559

Published: April 10, 2025

Tumor necrosis factor alpha (TNF-α) is a pro-inflammatory cytokine associated with TNF receptor 1 (TNFR1) and 2 (TNFR2), which play important roles in several inflammatory diseases. There growing interest developing alternative molecules that can be used as blockers. In this study, we focused on TNF-α-, TNFR1-, TNFR2-mimicking peptides to inhibit TNF-α binding various ways. Six (OB1, OB2, OB5, OB6, OB7, OB8) were developed bind TNFR1, TNFR2, TNF-α. OB1 OB2 bound lower Kd values of 300 46.7 nM, respectively, compared previously published sequences. These synthetic directly indirectly inhibited vitro without cytotoxicity L929 cells, significantly apoptosis the presence hTNF-α. Peptides study may prove useful for therapeutic inhibition

Language: Английский

---

Safety, Efficacy, and Effectiveness of Maternal Vaccination against Respiratory Infections in Young Infants

Seminars in Respiratory and Critical Care Medicine, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 21, 2024

Lower respiratory tract infection (LRTI) is a major cause of neonatal morbidity and mortality worldwide. Maternal vaccination an effective strategy in protecting young infants from LRTI, particularly the first few months after birth when infant most vulnerable, primary childhood vaccinations have not been administered. Additionally, maternal protects mother illness during pregnancy postnatal period, developing fetus adverse outcomes such as stillbirth prematurity. In this paper, we review safety, efficacy, effectiveness vaccines against LRTIs, pertussis, influenza, coronavirus disease 2019, syncytial virus.

Language: Английский

---